2,3,4,6-tetra-O-benzyl-D-galactopyranosyl bromide | 67145-38-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3,4,6-tetra-O-benzyl-D-galactopyranosyl bromide
• 英文别名: (3R,4S,5S,6R)-2-bromo-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxane
• CAS: 67145-38-4
• 化学式: C₃₄H₃₅BrO₅
• 分子量: 603.553
• InChiKey: WXYNLXPSTFTJJC-BJPULKCASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  40
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  46.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3,4,6-tetra-O-benzyl-D-galactopyranosyl bromide 在 4 A molecular sieve 、 四乙基溴化铵 、 DMTST 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 53.0h， 生成 2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl-(1->6)-2,3,4-tri-O-benzyl-α-D-galactopyranosyl-(1->3)-1,2,5,6-tetra-O-acetyl-α,β-D-galactofuranose
  参考文献：
  名称：

  Synthesis of the Leishmania LPG Core Heptasaccharyl myo-Inositol

  摘要：

  Total synthesis of the core heptasaccharyl myo-inositol, Galp(alpha1-6)Galp(alpha1-3)Galf(beta1-3)[Glcp(alpha1-PO4-6)Manp](alpha1-3)Manp(alpha1-4)GlcNp(alpha1-6)Ins-1-PO4, and the corresponding hexasaccharyl myo-inositol, Galp(alpha1-6)Galp(alpha1-3)Galf(beta1-3)Manp(alpha1-3)Manp(alpha1-4)GlcNp(alpha1-6)Ins-1-PO4, found in the lipophosphoglycans of Leishmania parasites are described. The target molecules contain synthetic challenges such as an unusual internal galactofuranosyl residue and an anomeric phosphodiester. The synthesis was accomplished using a convergent block synthetic strategy. Four building blocks, a trigalactoside, a dimannoside, a glucosyl inositolphosphate, and a glucosyl-alpha -1-H-phosphonate, all appropriately protected, were used. The trigalactoside was linked to the dimannoside followed by glycosylation with the glucosyl inositolphosphate to produce the fully protected hexasaccharyl myo-inositol. Subsequent oxidative coupling of the glucosyl-H-phosphonate formed the anomeric phosphodiester linkage to produce the protected heptasaccharyl myo-inositol. Both the assembly order of the subunits and sequence of deprotection were essential for the successful synthesis of these complex molecules. The deprotection was accomplished by deacetylation and clevage of benzyl ethers with sodium in liquid ammonia, followed by acidic deacetalization/desilylation to produce the target molecules.

  DOI：

  10.1021/ja001515t
• 作为产物：
  描述：

  2,3,4,6-tetra-O-benzyl-D-galactopyranosyl acetate 在 氢溴酸 作用下， 以 异丙醚 、 甲苯 为溶剂， 反应 1.5h， 生成 2,3,4,6-tetra-O-benzyl-D-galactopyranosyl bromide
  参考文献：
  名称：

  HEPATITIS C VIRUS INHIBITOR COMPRISING ALPHA-GLYCOSYLCERAMIDE AS THE ACTIVE INGREDIENT

  摘要：

  这项发明提供了一种用于感染了上述病毒的患者的人类丙型肝炎病毒生长抑制剂，其活性成分为α-糖基神经酰胺。这种丙型肝炎病毒的抑制剂包括一个由式(I)表示的化合物或其盐或溶剂。

  公开号：

  EP1541153A1

文献信息

• Bismuth(<scp>iii</scp>) triflate as a novel and efficient activator for glycosyl halides
  作者：Hayley B. Steber、Yashapal Singh、Alexei V. Demchenko

  DOI：10.1039/d1ob00093d

  日期：——

  Presented herein is the discovery that bismuth(III) trifluoromethanesulfonate (Bi(OTf)3) is an effective catalyst for the activation of glycosyl bromides and glycosyl chlorides. The key objective for the development of this methodology is to employ only one promoter in the lowest possible amount and to avoid using any additive/co-catalyst/acid scavenger except molecular sieves. Bi(OTf)3 works well

  本文提出了三氟甲磺酸铋( III )(Bi(OTf) 3 )是用于活化糖基溴和糖基氯的有效催化剂的发现。开发该方法的关键目标是仅使用尽可能低量的一种促进剂，并避免使用除分子筛之外的任何添加剂/助催化剂/酸清除剂。 Bi(OTf) 3在促进差异保护的葡萄糖基、半乳糖基和甘露糖基卤化物与多种糖基受体的糖苷化方面效果良好。大多数反应在仅 35% 的绿色光稳定 Bi(OTf) 3催化剂存在下在 1 小时内完成。
• An easy access to halide ion-catalytic α-glycosylation using carbon tetrabromide and triphenylphosphine as multifunctional reagents
  作者：Yuko Shingu、Yoshihiro Nishida、Hirofumi Dohi、Kazukiyo Kobayashi

  DOI：10.1039/b303984f

  日期：——

  The reaction of a 2-O-benzyl-1-hydroxy sugar with CBr4 and Ph3P generates a glycosyl bromide in situ, which is coupled with an acceptor alcohol in the presence of N,N-tetramethylurea to afford an α-glycosyl product virtually quantitatively. In a proposed pathway, the reagent combination plays multiple roles such as the generation of a glycosyl donor, the activation of glycosylation, and the dehydration of the reaction system. These roles allow a simple α-glycosylation to be performed without special attention to dehydration. Various α-glycosyl (D-gluco-, D-galacto- and L-fuco-) products including glycosyl glycerols and cholesterols have been prepared with this method.

  2-O-苄基-1-羟基糖与CBr4和Ph3P反应生成一种即时的糖基溴化物，该溴化物在N,N-四甲基脲存在下与受体醇耦合，几乎定量地得到α-糖基产物。在提出的反应途径中，试剂组合扮演了多个角色，如糖基供体的生成、糖基化的活化以及反应体系的脱水作用。这些角色使得一个简单的α-糖基化反应得以进行，而无需特别关注脱水步骤。利用这种方法已经制备了多种α-糖基（D-葡萄糖、D-半乳糖和L-岩藻糖）产物，包括糖基甘油和胆固醇。
• Stereocontrolled α-Galactosylation under Cooperative Catalysis
  作者：Melanie Shadrick、Yashapal Singh、Alexei V. Demchenko

  DOI：10.1021/acs.joc.0c01279

  日期：2020.12.18

  A recent discovery of a cooperative catalysis comprising a silver salt and an acid led to a dramatic improvement in the way glycosyl halides are glycosidated. Excellent yields have been achieved, but the stereoselectivity achieved with 2-O-benzylated donors was poor. Reported herein is our first attempt to refine the stereoselectivity of the cooperatively catalyzed galactosylation reaction. Careful

  最近发现的包含银盐和酸的协同催化导致糖基卤化物糖苷化方式的显着改进。已经实现了极好的产率，但是用 2- O-苄基化供体实现的立体选择性很差。本文报道的是我们首次尝试改进协同催化的半乳糖基化反应的立体选择性。仔细优化反应条件以及研究远程保护基团的作用，对具有不同保护的半乳糖基供体的各种糖基受体的 α-半乳糖基化进行了出色的立体控制。
• Synthesis of blood group A and B (type 2) tetrasaccharides. A strategy with fucosylation at the last stage
  作者：Roman A. Kunetskiy、Galina V. Pazynina、Igor A. Ivanov、Nicolai V. Bovin

  DOI：10.1016/j.carres.2020.108192

  日期：2020.12

  The traditionally used strategy for the synthesis of blood group A and B tetrasaccharides includes 2'-O-fucosylation of lactosamine followed by insertion of an α1-3 linked N-acetylgalactosamine or a galactose moiety. Here, we report the synthesis of 3-aminopropyl glycosides of A (type 2) and B (type 2) tetrasaccharides via an alternative sequence, i.e. α-galactosaminylation (or α-galactosylation) followed

  传统上用于合成血型 A 和 B 四糖的策略包括乳糖胺的 2'-O-岩藻糖基化，然后插入 α1-3 连接的 N-乙酰半乳糖胺或半乳糖部分。在这里，我们报告了通过替代序列合成 A（2 型）和 B（2 型）四糖的 3-氨基丙基糖苷，即 α-半乳糖胺化（或 α-半乳糖基化），然后是 α-岩藻糖基化。该策略使我们能够合成不含岩藻糖的三糖 GalNAcα1-3Galβ1-4GlcNAc 和 Galα1-3Galβ1-4GlcNAc，它们是利用针对三糖的人类天然抗体进行免疫治疗的有前景的靶标。该方案的关键阶段是在具有第二个 (3-OH) 未保护基团的中间体三糖中对 βGal 的 2'-OH 基团进行选择性氯乙酰化。
• Synthesis of α-Galactosyl Ceramide (KRN7000) and Analogues Thereof via a Common Precursor and Their Preliminary Biological Assessment
  作者：Mario Michieletti、Antonio Bracci、Federica Compostella、Gennaro De Libero、Lucia Mori、Silvia Fallarini、Grazia Lombardi、Luigi Panza

  DOI：10.1021/jo8019994

  日期：2008.11.21

  practical synthesis of alpha-GalCer and of its analogues is presented, opening the chance to easily modify the sphingosine chain. The common precursor is a disaccharide, obtained by coupling tetra-O-benzyl-D-galactose with allyl 2,3-O-isopropylidene-D-lyxofuranoside. Introduction of alkyl chains via Wittig reaction (for alpha-GalCer and OCH) or via Williamson reaction (for oxa analogues) followed by

  提出了一种新的实用的α-GalCer及其类似物的合成方法，这为轻松修饰鞘氨醇链提供了机会。常见的前体是二糖，其通过将四-O-苄基-D-半乳糖与烯丙基2,3-O-异亚丙基-D-呋喃呋喃糖苷偶联而获得。通过Wittig反应（对于α-GalCer和OCH）或Williamson反应（对于oxa类似物）引入烷基链，然后进行标准合成步骤，可以使人们有效地获得此类化合物。当表达CD1d的细胞呈递时，这些类似物能够激活iNKT细胞。